Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 18:5:196.
doi: 10.3389/fcvm.2018.00196. eCollection 2018.

Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet

Affiliations
Review

Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet

Magnus Bäck et al. Front Cardiovasc Med. .

Abstract

The physicochemical deposition of calcium-phosphate in the arterial wall is prevented by calcification inhibitors. Studies in cohorts of patients with rare genetic diseases have shed light on the consequences of loss-of-function mutations for different calcification inhibitors, and genetic targeting of these pathways in mice have generated a clearer picture on the mechanisms involved. For example, generalized arterial calcification of infancy (GACI) is caused by mutations in the enzyme ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (eNPP1), preventing the hydrolysis of ATP into pyrophosphate (PPi). The importance of PPi for inhibiting arterial calcification has been reinforced by the protective effects of PPi in various mouse models displaying ectopic calcifications. Besides PPi, Matrix Gla Protein (MGP) has been shown to be another potent calcification inhibitor as Keutel patients carrying a mutation in the encoding gene or Mgp-deficient mice develop spontaneous calcification of the arterial media. Whereas PPi and MGP represent locally produced calcification inhibitors, also systemic factors contribute to protection against arterial calcification. One such example is Fetuin-A, which is mainly produced in the liver and which forms calciprotein particles (CPPs), inhibiting growth of calcium-phosphate crystals in the blood and thereby preventing their soft tissue deposition. Other calcification inhibitors with potential importance for arterial calcification include osteoprotegerin, osteopontin, and klotho. The aim of the present review is to outline the latest insights into how different calcification inhibitors prevent arterial calcification both under physiological conditions and in the case of disturbed calcium-phosphate balance, and to provide a consensus statement on their potential therapeutic role for arterial calcification.

Keywords: arterial calcification; fetuin; gla proteins; klotho; osteopontin; osteoprotegerin; pyrophosphate.

PubMed Disclaimer

References

    1. Rashdan NA, Rutsch F, Kempf H, Varadi A, Leftheriotis G, MacRae VE. New perspectives on rare connective tissue calcifying diseases. Curr Opin Pharmacol. (2016) 28:14–23. 10.1016/j.coph.2016.02.002 - DOI - PubMed
    1. Fleisch H, Bisaz S. Mechanism of calcification: inhibitory role of pyrophosphate. Nature (1962) 195:911. 10.1038/195911a0 - DOI - PubMed
    1. Lomashvili KA, Narisawa S, Millan JL, O'Neill WC. Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int. (2014) 85:1351–6. 10.1038/ki.2013.521 - DOI - PMC - PubMed
    1. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science (2000) 289:265–70. 10.1126/science.289.5477.265 - DOI - PubMed
    1. Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Varadi A, et al. . ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. (2014) 34:1985–9. 10.1161/ATVBAHA.114.304017 - DOI - PMC - PubMed